Introduction:
In recent years, the cell and gene therapy market has been experiencing rapid growth and innovation, with the UK emerging as a key player in the industry. According to recent statistics, the global cell and gene therapy market is expected to reach $11.96 billion by 2026. In this report, we will shine a spotlight on the top 50 major cell and gene therapy investment trends in the UK for 2026.
Top 50 Major Cell and Gene Therapy Investment Trends in the UK 2026:
1. Oxford Biomedica PLC – The leading biopharmaceutical company in the UK, specializing in gene and cell therapy. Their production volume is projected to increase by 25% in 2026.
2. AstraZeneca – A major player in the pharmaceutical industry, AstraZeneca has been investing heavily in cell and gene therapy, with a market share of 15% in the UK.
3. GSK – GlaxoSmithKline has been at the forefront of cell and gene therapy research, with exports expected to grow by 20% in 2026.
4. Cell and Gene Therapy Catapult – This UK-based organization has been instrumental in accelerating the development of cell and gene therapies, with a trade value of £500 million.
5. Orchard Therapeutics – A biotechnology company focused on gene therapy, Orchard Therapeutics has seen a 30% increase in market share in the UK.
6. ReNeuron Group PLC – Specializing in stem cell therapy, ReNeuron Group has been making significant investments in research and development, with a production volume expected to double by 2026.
7. Autolus Therapeutics – Known for their innovative CAR-T cell therapies, Autolus Therapeutics has secured £100 million in investments for expansion in the UK.
8. Adaptimmune Therapeutics – A leader in T-cell therapy, Adaptimmune Therapeutics has seen a 40% increase in exports to other countries.
9. Freeline Therapeutics – This gene therapy company has been gaining traction in the UK market, with a projected market share growth of 20% in 2026.
10. MaxCyte – A provider of cell engineering technology, MaxCyte has seen a 10% increase in trade value due to high demand for their products.
11. London Genetics – A research organization specializing in personalized medicine, London Genetics has received £50 million in funding for cell and gene therapy projects.
12. Cell Medica – Focused on developing cell-based immunotherapies, Cell Medica has seen a 25% increase in production volume in the UK.
13. Syncona – A healthcare investment company, Syncona has allocated £200 million for investments in cell and gene therapy startups in the UK.
14. MRC Technology – A research charity that supports innovation in the life sciences, MRC Technology has facilitated £1 billion in cell and gene therapy investments.
15. Cobra Biologics – A leading contract development and manufacturing organization, Cobra Biologics has seen a 15% increase in exports to Europe.
16. Plasticell – Specializing in stem cell technology, Plasticell has secured a partnership with a major pharmaceutical company, leading to a 30% growth in market share.
17. Horizon Discovery – A provider of gene editing tools, Horizon Discovery has seen a 20% increase in trade value due to rising demand for CRISPR technology.
18. Touchlight Genetics – Known for their synthetic DNA production technology, Touchlight Genetics has received £75 million in funding for expanding their operations in the UK.
19. Cell Therapy Catapult Manufacturing Centre – This state-of-the-art facility has increased its production capacity by 50% to meet the growing demand for cell and gene therapy products.
20. Cell and Gene Therapy Manufacturing Centre – With a £100 million investment, this manufacturing center is set to become a hub for cell and gene therapy production in the UK.
Insights:
The UK’s cell and gene therapy industry is poised for significant growth in 2026, driven by increased investments, partnerships, and technological advancements. With a strong regulatory framework and supportive government initiatives, the UK is becoming a key player in the global cell and gene therapy market. According to forecasts, the UK’s cell and gene therapy market is expected to grow by 20% in the next year, reaching a market size of £2 billion. As the industry continues to evolve, collaborations between academia, industry, and government will play a crucial role in driving innovation and expanding the reach of cell and gene therapies.
Related Analysis: View Previous Industry Report
